Venture capital's appetite for mega-rounds cooled this week, but AI infrastructure still commanded the largest check. Modal Labs, a New York-based provider of cloud infrastructure for AI inference, closed a $750 million Series D round led by Accel at a $15.75 billion valuation.

What You Need to Know

Modal Labs exceeded a $1 billion annual revenue run rate before this round, signaling that AI infrastructure demand remains robust even as overall deal sizes contract. The week produced only two financings above $200 million, a notable pullback from the pace of earlier quarters. Biotech and insurance also attracted significant capital, with Soufflé Therapeutics and Stand each closing nine-figure rounds. The concentration of capital in AI-adjacent infrastructure suggests investors are prioritizing picks-and-shovels plays over application-layer bets.

Why This Matters

The Modal Labs round underscores a structural shift in venture capital: investors are increasingly funding the compute layer that powers AI models rather than the models themselves. This mirrors the early cloud computing era, when infrastructure providers like AWS captured value before application companies matured.

For founders building AI applications, the implication is stark. Access to reliable, scalable inference infrastructure is becoming a competitive moat, and companies that secure long-term compute partnerships may outpace rivals that rely on spot capacity. The $15.75 billion valuation places Modal Labs in rare air for a private infrastructure company, suggesting public markets may soon see a wave of AI infrastructure IPOs.

What You Need to Know

The week's funding activity reveals a market that is still writing large checks but with greater selectivity. Nine of the ten largest rounds went to U.S.-based companies, with sectors ranging from RNA therapies to semiconductor systems. The geographic spread includes Austin, Boston, Menlo Park, Portland and San Francisco.

Construction automation unicorn Icon secured $200 million in Series D funding led by Baillie Gifford and BlackRock. The company, based in Austin, says it is on pace for 4x revenue growth in 2026. Its robotic construction systems, known for 3D-printed homes, represent a bet on automating a labor-constrained industry.

$750M

Modal Labs Series D

$15.75B

Modal Labs valuation

$200M

Icon Series D

Biotech and Healthcare Draw Nine-Figure Checks

Beyond AI infrastructure, the life sciences sector demonstrated enduring appeal. Soufflé Therapeutics, a Boston-based developer of RNA therapies, raised $135 million in Series B funding led by Juvia Group as part of a large syndicate. The round highlights continued investor interest in novel therapeutic platforms.

Estuary Biotherapeutics launched with $103 million in financing, including a $93 million Series A round led by RA Capital Management and $10 million in previously undisclosed seed capital. The Menlo Park, California-based company develops genetic medicines for patients with serious kidney diseases.

Health AI also made the list. Suki, based in Redwood City, California, announced a $90 million Series E financing from backers including Healthier Capital and Crosslink Capital. The company provides AI tools that turn clinical conversations into intelligence for documentation, coding and other healthcare workflows.

Insurance and Caregiving Platforms Attract Growth Capital

Stand, a provider of insurance for homes in areas at higher risk of natural disasters, secured $70 million in Series C funding at a $1 billion valuation. Saga Ventures led the financing for the 3-year-old, San Francisco-based company. The round reflects growing investor attention to climate risk and insurance innovation.

Abby Care, a platform for family members to become certified, paid caregivers and deliver care at home, closed on $82 million in Series C funding. Transformation Capital led the financing for the 5-year-old, San Francisco-based startup. The deal underscores demand for solutions addressing caregiver shortages and aging-in-place preferences.

Semiconductor and AI Spend Management Round Out the List

Mueon Corp., a semiconductor systems company building a modular platform for AI and hyperscale computing, completed a $65 million Series A funding round. Maverick Silicon led the financing for the Portland, Oregon-based company. The investment signals continued interest in hardware that supports AI workloads.

North.cloud, a New York-based provider of an infrastructure spend intelligence and automation platform, raised $60 million in a Series B round led by PeakSpan Capital. The company helps enterprises manage and optimize their cloud and AI spending, a growing concern as compute costs rise.

  • Modal Labs: $750M Series D at $15.75B valuation, led by Accel.
  • Icon: $200M Series D led by Baillie Gifford and BlackRock.
  • Soufflé Therapeutics: $135M Series B led by Juvia Group.
  • Estuary Biotherapeutics: $103M total, including $93M Series A led by RA Capital Management.

The week's activity suggests that while the era of indiscriminate mega-rounds may be fading, capital remains available for companies with clear infrastructure or therapeutic value propositions. Investors are rewarding focus over breadth.